British Journal of Cancer - Table of Contents alert Volume 118 Issue 9

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 118, Issue 9 In this issue Review Article Article Correspondence Also new AOP   Review Article Progress in preventive therapy for cancer: a reminiscence and personal viewpoint Jack Cuzick British Journal of Cancer 2018 118 :1155 - 1161; April 23, 2018; 10.1038/s41416-018-0039-4   Abstract | Full Text Article A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma D. H. Palmer, Y. T. Ma, M. Peck-Radosavljevic, P. Ross, J. Graham et al. British Journal of Cancer 2018 118 :1162 - 1168; March 22, 2018; 10.1038/s41416-018-0051-8   Abstract | Full Text Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study Jin Won Kim, Yun-Gyoo Lee, In Gyu Hwang, Hong Suk Song, Su Jin Koh et al. British Journal of Cancer 2018 118 :1169 - 1175; March 26, 2018; 10.1038/s41416-018-0037-6   Abstract | Full Text Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma Robert J. Motzer, Bernard Escudier, Thomas Powles, Christian Scheffold & Toni K. Choueiri British Journal of Cancer 2018 118 :1176 - 1178; March 26, 2018; 10.1038/s41416-018-0061-6   Abstract | Full Text The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma Helena Polena, Julie Creuzet, Maeva Dufies, Adama Sidibé, Abir Khalil-Mgharbel et al. British Journal of Cancer 2018 118 :1179 - 1188; March 22, 2018; 10.1038/s41416-018-0054-5   Abstract | Full Text The mechanism study of lentiviral vector carrying methioninase enhances the sensitivity of drug-resistant gastric cancer cells to Cisplatin Lin Xin, Wei-Feng Yang, Hou-Ting Zhang, Yi-Fan Li & Chuan Liu British Journal of Cancer 2018 118 :1189 - 1199; March 26, 2018; 10.1038/s41416-018-0043-8   Abstract | Full Text Quantitative proteomic profiling of primary cancer-associated fibroblasts in oesophageal adenocarcinoma Antigoni Manousopoulou, Annette Hayden, Massimiliano Mellone, Diana J. Garay-Baquero, Cory H. White et al. British Journal of Cancer 2018 118 :1200 - 1207; March 29, 2018; 10.1038/s41416-018-0042-9   Abstract | Full Text In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics Keely M McNamara, Fouzia Guestini, Torill Sauer, Joel Touma, Ida Rashida Bukholm et al. British Journal of Cancer 2018 118 :1208 - 1216; March 22, 2018; 10.1038/s41416-018-0034-9   Abstract | Full Text Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study Julia Bergheim, Alexander Semaan, Heidrun Gevensleben, Susanne Groening, Andreas Knoblich et al. British Journal of Cancer 2018 118 :1217 - 1228; April 03, 2018; 10.1038/s41416-018-0035-8   Abstract | Full Text WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer Flore-Anne Poujade, Aarren Mannion, Nicholas Brittain, Andrew Theodosi, Ellie Beeby et al. British Journal of Cancer 2018 118 :1229 - 1237; March 15, 2018; 10.1038/s41416-018-0056-3   Abstract | Full Text Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma Guillermo de Velasco, Stephanie A. Wankowicz, Russell Madison, Siraj M. Ali, Craig Norton et al. British Journal of Cancer 2018 118 :1238 - 1242; April 20, 2018; 10.1038/s41416-018-0064-3   Abstract | Full Text NF1 mutations in conjunctival melanoma S. L. Scholz, I. Cosgarea, D. Süßkind, R. Murali, I. Möller et al. British Journal of Cancer 2018 118 :1243 - 1247; March 21, 2018; 10.1038/s41416-018-0046-5   Abstract | Full Text Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer Teemu J. Murtola, Ville JY Vihervuori, Jorma Lahtela, Kirsi Talala, Kimmo Taari et al. British Journal of Cancer 2018 118 :1248 - 1254; March 22, 2018; 10.1038/s41416-018-0055-4   Abstract | Full Text First-degree relatives of cancer patients: a target group for primary prevention? A cross-sectional study Ulrike Haug, Oliver Riedel, Constanze Cholmakow-Bodechtel & Louise Olsson British Journal of Cancer 2018 118 :1255 - 1261; March 21, 2018; 10.1038/s41416-018-0057-2   Abstract | Full Text Height and overall cancer risk and mortality: evidence from a Mendelian randomisation study on 310,000 UK Biobank participants Jue-Sheng Ong, Jiyuan An, Matthew H. Law, David C. Whiteman, Rachel E. Neale et al. British Journal of Cancer 2018 118 :1262 - 1267; March 27, 2018; 10.1038/s41416-018-0063-4   Abstract | Full Text Impact of NICE guidance on tamoxifen prescribing in England 2011–2017: an interrupted time series analysis Helen J. Curtis, Alex J. Walker & Ben Goldacre British Journal of Cancer 2018 118 :1268 - 1275; April 23, 2018; 10.1038/s41416-018-0065-2   Abstract | Full Text Correspondence Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’ Matthew Dankner & April A. N. Rose British Journal of Cancer 2018 118 :1276 - 1277; March 22, 2018; 10.1038/s41416-018-0012-2   Abstract | Full Text Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'' Eiji Shinozaki, Takayuki Yoshino & Katsuya Tsuchihara British Journal of Cancer 2018 118 :1278 - 1279; March 22, 2018; 10.1038/s41416-018-0040-y   Abstract | Full Text Advertisement Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours. Click here to sign up. Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.